Sharma Charu, Al Kaabi Juma M, Nurulain Syed M, Goyal Sameer N, Kamal Mohammad Amjad, Ojha Shreesh
Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, UAE.
Curr Pharm Des. 2016;22(21):3237-64. doi: 10.2174/1381612822666160311115226.
β-Caryophyllene (BCP) is a natural bicyclic sesquiterpene abundantly found in essential oils from various spices, fruits and medicinal as well as ornamental plants. It is approved by United States Food and Drug Administration and European agencies as food additive, taste enhancer and flavoring agent and termed as a phytocannabinoid.
All the available literature on BCP and its synonyms were collected through different literature databases.
BCP was found to elicit a full agonist action on cannabinoid type 2 (CB2) receptors, a G-protein coupled receptor representing important therapeutic target in several diseases. Activation of CB2 receptors notably appeared devoid of psychotropic adverse effect of cannabinoids contrary to the CB1 receptors. In addition, it activates peroxisome proliferated activator receptors (PPARs) isoforms; PPAR-α &-γ and inhibits pathways triggered by the activation of toll like receptor complex; CD14/TLR4/MD2, reduce immuneinflammatory processes and exhibit synergy with µ-opioid receptor dependent pathways. Additionally, it found as potent antagonist of homomeric nicotinic acetylcholine receptors (α7-nAChRs) and devoid of effects mediated by serotonergic and GABAergic receptors. It also modulates numerous molecular targets by altering their gene expression, signaling pathways or through direct interaction. Various pharmacological activities such as cardioprotective, hepatoprotective, gastroprotective, neuroprotective, nephroprotective, antioxidant, anti-inflammatory, antimicrobial and immune-modulator have been reported in experimental studies. It has shown potent therapeutic promise in neuropathic pain, neurodegenerative and metabolic diseases.
The present review provides a comprehensive insight of pharmacological and therapeutic potential of BCP, its molecular mechanism and signaling pathways in different pathological conditions. The review also examines the possibility of its further development as a novel candidate for various pathologies considering the polypharmacological and multifaceted therapeutic properties potential along with favorable oral bioavailability, lipophilicity and physicochemical properties.
β-石竹烯(BCP)是一种天然双环倍半萜,大量存在于各种香料、水果、药用植物以及观赏植物的精油中。它被美国食品药品监督管理局和欧洲相关机构批准作为食品添加剂、味觉增强剂和调味剂,并且被称为一种植物大麻素。
通过不同的文献数据库收集了所有关于BCP及其同义词的可用文献。
发现BCP对2型大麻素(CB2)受体具有完全激动剂作用,CB2受体是一种G蛋白偶联受体,是多种疾病中的重要治疗靶点。与CB1受体相反,激活CB2受体明显没有大麻素的精神副作用。此外,它可激活过氧化物酶体增殖激活受体(PPARs)亚型;PPAR-α和 -γ,并抑制由Toll样受体复合物激活引发的途径;CD14/TLR4/MD2,减少免疫炎症过程,并与μ-阿片受体依赖性途径表现出协同作用。此外,它被发现是同源烟碱型乙酰胆碱受体(α7-nAChRs)的有效拮抗剂,并且没有血清素能和GABA能受体介导的作用。它还通过改变基因表达、信号通路或直接相互作用来调节众多分子靶点。在实验研究中已报道了各种药理活性,如心脏保护、肝脏保护、胃保护、神经保护、肾脏保护、抗氧化、抗炎、抗菌和免疫调节作用。它在神经性疼痛、神经退行性疾病和代谢性疾病中显示出强大的治疗前景。
本综述全面深入地探讨了BCP的药理和治疗潜力、其在不同病理条件下的分子机制和信号通路。考虑到其多药理学和多方面的治疗特性潜力以及良好的口服生物利用度、亲脂性和理化性质,本综述还研究了其作为各种疾病新候选药物进一步开发的可能性。